PIP2 Stabilization for Cerebral Blood Flow Restoration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments are ineffective for cerebral small vessel diseases, which significantly contribute to stroke and dementia, and there is a lack of understanding of the underlying biological mechanisms, particularly in how cerebral blood flow is compromised in these conditions.

Innovation Solution

Administering a therapeutic agent that increases the level of phosphatidylinositol 4,5-bisphosphate (PIP2) to treat conditions characterized by reduced cerebral blood flow, such as cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), by restoring capillary endothelial cell function and neurovascular coupling.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for cerebral small vessel diseases, then general cardiovascular conditions may be managed, but cerebral blood flow remains compromised and disease progression continues

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidreduced cerebral blood flow

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameter of PIP2 concentration in capillary endothelial cells by administering PIP2-stabilizing compounds. This parameter change restores Kir2.1 channel function and thereby improves cerebral blood flow control, directly addressing the harmful effect of reduced CBF in SVDs while conventional treatments fail to achieve this specific molecular correction.

Inventive Principle:

Principle #35Parameter changes

2Stability of the object's composition

If the ADAM17/HB-EGF/EGFR signaling axis is downregulated, then TIMP3 accumulation occurs in NOTCH3 deposits, but cerebral blood flow control is impaired and functional abnormalities develop

Engineering Contradiction:

ImproveTIMP3 accumulation in NOTCH3 depositsVSAvoidcerebral blood flow control

Core Design Contradiction:

Stability of the object's compositionVSReliability

Solution Approach 1:

The patent uses PIP2-stabilizing compounds as intermediaries that act downstream of the ADAM17/HB-EGF/EGFR pathway. By stabilizing PIP2, these compounds bypass the upstream signaling defects caused by TIMP3 accumulation and NOTCH3 mutations, directly restoring Kir2.1 channel function and CBF control without needing to reverse the upstream pathological changes.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If Kir2.1 channel function is lost in capillary endothelial cells, then neurovascular coupling is disrupted, but no specific treatment currently exists to restore this function

Engineering Contradiction:

Improveavailability of specific treatmentVSAvoidneurovascular coupling function

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent enables self-service by using PIP2-stabilizing compounds that allow capillary endothelial cells to self-correct their Kir2.1 channel dysfunction. The compounds stabilize endogenous PIP2 levels, enabling the cells to autonomously restore their electrochemical signaling capacity and neurovascular coupling function without requiring external cellular repair mechanisms or complex therapeutic interventions.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The approach effectively restores cerebral blood flow and functional hyperemia, addressing the deficits in CADASIL and other small vessel diseases by modulating Kir2.1 channels and improving cerebrovascular function.

Implementation Method 1

The approach effectively restores cerebral blood flow and functional hyperemia, addressing the deficits in CADASIL and other small vessel diseases by modulating Kir2.1 channels

Methodology Applied

Scientific EffectIon channel modulation:

Data Source

PatentUS20220168325A1Methods to promote cerebral blood flow in the brain

Publication Date: 2022.06.02 UNIVERSITY OF VERMONT

AI summary

The present application relates to methods for treating conditions characterized by reduced cerebral blood flow that include selecting a subject having a condition characterized by reduced cerebral blood flow. A therapeutic agent that increases the levels of PIP2 is administered under conditions effective to treat the condition in the subject. Also disclosed are methods for treating CADASIL as well as methods for restoring cerebral blood flow and functional hyperemia.